医疗器械公司Embecta Corp近日调整了全年业绩预期，其最新指引显示，第二季度对美国市场业务产生负面影响的运营环境因素，预计将在本财年剩余时间内持续存在。
这一修正后的展望反映出公司面临的核心挑战尚未出现缓解迹象。管理层在评估当前市场动态后认为，影响胰岛素注射装置等糖尿病护理产品销售的不利条件，包括供应链调整周期和医保政策变化，可能延续至下半年。
尽管Embecta在全球糖尿病管理领域拥有深厚技术积累，但美国作为其关键市场，近期业务波动直接促使公司采取更谨慎的财务预测。分析师指出，这种前瞻性调整既体现了管理层对现实挑战的清醒认知，也为投资者提供了更准确的业绩预期基准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.